ImmuCell reports preliminary Q4 2024 sales of $7.8M, up 52% YoY; full year $26.5M

IMMUCELL CORP /DE/

Q4 2024 product sales $7.8M vs $5.1M in Q4 2023 (+52%); FY2024 sales $26.5M vs $17.5M (+52%).
Annualized Q4 production output ~103% of estimated $30M/year capacity; backlog fell to $4.4M from $9.4M.
Contract manufacturer submitted response to FDA inspection observations; company filed Non-Administrative NADA for Re-Tain® in January.
Conference call to discuss full unaudited results on February 26, 2025 at 9:00 AM ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.